GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

4SC Receives Patent on Rheumatoid Arthritis Candidate

  • 4SC was granted a patent related to its rheumatoid arthritis drug candidate, SC12267. The patent protects the DHODH inhibitor. SC 12267 is currently in Phase IIa trials.

    In addition, the patent also covers further back-up substances related to SC12267, medical formulations, and the treatment of patients with SC12267. The patent will apply until 2020.

    This expansion on 4SC’s patent portfolio, explains Ulrich Dauer, CEO, creates “the ideal conditions for a potential licensing partnership within the scope of this project."


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »